Revance therapeutics, inc. (RVNC)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss

-185,996

-159,400

-154,716

-146,150

-142,835

-142,568

-137,859

-135,676

-128,468

-120,587

-111,512

-98,839

-96,568

-89,300

-84,562

-85,759

-77,962

-73,476

-65,594

-60,396

-56,893

-62,917

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Interest for 2013 Notes and Essex Notes upon issuance, non-cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

271

0

0

0

Capitalized interest

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

972

0

0

0

Effective interest on financing obligations

-

-

-

-

-

-

-

-

-

-

0

0

377

-

433

461

445

344

188

128

39

28

0

0

0

Non-cash in-process research and development

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of discount on debt and capital leases

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

57

133

209

1,250

0

0

0

Amortization of debt issuance cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

94

143

190

203

0

0

0

Change in fair value of derivative liabilities associated with convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,032

0

0

0

Change in fair value of derivative liability associated with Medicis settlement

-

-

-

-

-

-

-

-

-

-

0

0

-654

-

-528

-348

155

127

166

220

54

-320

0

0

0

Change in fair value of common stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,151

0

0

0

Change in fair value of convertible preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

210

0

0

0

Extinguishment of warrant liability upon exercise of put option

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,356

0

0

0

Loss on extinguishment of 2013 Notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,331

0

0

0

Stock-based compensation

20,307

17,922

16,733

16,522

16,274

16,273

15,832

14,886

14,233

13,230

12,789

12,398

12,131

11,953

14,058

13,893

13,048

12,388

9,233

8,927

8,037

6,530

0

0

0

Amortization of debt discount and issuance costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

1,726

1,623

1,553

1,501

1,468

1,473

1,468

1,458

1,445

1,477

1,619

1,808

1,995

2,076

2,107

2,094

2,051

0

0

0

Amortization of discount on investments

2,501

2,637

2,414

1,974

1,497

1,103

876

526

39

-410

-565

-752

-950

-1,212

-1,266

-1,259

-1,057

-601

0

0

0

-

-

-

-

Other non-cash operating activities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-cash operating activities

-

-

-

-

-

175

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock for service rendered

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Changes in operating assets and liabilities:
Accounts receivable

0

-27,000

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

826

1,377

-804

-1,156

1,619

2,911

4,924

982

-3,683

-4,849

-4,863

6,686

6,464

5,621

5,910

-146

141

192

-1,521

71

-1,077

999

0

0

0

Operating lease right of use assets

-2,142

1,868

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-current assets

-1,652

-1,578

-1,047

-1,273

2,060

1,871

1,834

2,190

182

403

639

655

82

151

-5

-374

-242

-29

359

911

581

1,621

0

0

0

Accounts payable

4,165

-360

-152

2,328

-776

1,691

651

1,180

203

2,607

3,502

1,143

1,536

953

-15

525

1,055

-692

-352

-253

-2,650

-3,399

0

0

0

Accruals and other liabilities

3,490

3,565

3,131

1,848

1,170

1,488

2,047

-3,657

-4,725

-690

833

9,228

9,503

7,502

5,904

809

2,042

3,179

4,229

3,015

1,689

2,311

0

0

0

Deferred revenue

5,807

4,587

34,190

26,874

26,187

51,272

21,758

24,120

24,807

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

Operating lease liabilities

-3,008

1,147

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-549

0

0

0

Payments against Medicis liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,073

0

0

0

Net cash used in operating activities

-138,036

-106,161

-103,794

-97,249

-104,516

-104,246

-101,501

-97,561

-85,294

-95,342

-80,414

-73,299

-65,339

-59,827

-62,810

-62,167

-58,323

-55,669

-48,340

-47,325

-46,993

-55,073

0

0

0

CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments

363,417

331,362

331,282

267,684

243,003

314,911

212,197

212,197

199,265

36,028

156,955

156,954

156,955

280,681

159,754

160,766

213,841

54,087

0

0

0

-

-

-

-

Purchases of property and equipment

2,693

3,238

4,574

6,122

7,007

6,991

5,855

3,353

3,297

2,525

2,555

2,183

1,276

1,670

1,631

2,030

2,217

3,328

4,380

5,849

7,791

6,975

0

0

0

Purchase of intangible assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of investments

346,500

317,000

279,000

245,000

171,000

146,000

146,790

129,790

149,695

157,445

129,255

207,255

200,350

207,650

140,050

47,050

16,050

1,000

0

0

0

-

-

-

-

Purchases of property and equipment

-

-

-

-

-

1,541

1,537

146

15

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

1,000

1,000

1,000

1,000

0

0

0

0

-

-

-

-

Change in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

CASH FLOWS FROM FINANCING ACTIVITIES

-19,720

-17,592

10,590

40,031

-10,149

-107,026

-69,825

-85,714

-52,952

118,792

-30,353

48,020

40,321

-75,499

-22,210

-116,621

-199,083

-56,415

-58,467

-58,925

-7,791

-6,975

0

0

0

Proceeds from issuance of common stock in connection with offerings, net of commissions and discount
Payments to settle warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,438

0

0

0

Payment of offering costs

-

-

-

-

-

366

569

743

680

644

441

328

411

243

243

182

37

0

0

0

0

-

-

-

-

Proceeds from issuance of common stock, net of deferred initial public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

102,672

0

0

0

Proceeds from issuance of convertible notes and notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,750

0

0

0

Proceeds from issuance of convertible senior notes

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock in connection with offerings, net of commissions and discount

119,451

211,970

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from Issuance of Common Stock

-

-

-

-

-

-

-

-

-

38,760

38,760

29,100

26,217

0

0

0

0

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options and common stock warrants

1,491

937

950

1,938

4,693

5,292

7,275

6,842

4,976

4,569

2,515

2,272

1,350

1,649

3,265

3,104

3,089

2,753

1,107

2,055

1,929

1,771

0

0

0

Payments for Derivative Instrument, Financing Activities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of convertible senior notes transaction costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net settlement of restricted stock awards for employee taxes

1,730

1,378

1,535

1,547

1,595

2,212

2,049

1,989

1,962

573

578

563

560

507

590

714

1,217

993

0

0

0

-

-

-

-

Payment of offering costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments made on financing obligations

-

-

-

-

-

932

1,841

2,726

3,624

3,636

3,646

3,658

3,634

3,541

3,452

3,367

3,365

2,598

1,850

1,118

310

228

0

0

0

Principal payments made on notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,652

8,738

10,862

12,926

12,316

0

0

0

Net cash provided by financing activities

379,136

221,657

106,994

107,970

110,872

1,782

160,284

168,512

168,721

195,944

36,610

26,823

22,962

-2,642

125,077

135,092

144,552

142,592

9,740

-716

120,573

229,091

0

0

0

NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH

-

-

-

-

-

-209,490

-11,042

-14,763

30,475

219,394

-74,157

1,544

-2,056

-137,968

40,057

-43,696

-112,854

30,508

-97,067

-106,966

65,789

167,043

0

0

0

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Issuance of common stock in connection with the Teoxane Agreement

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment purchases included in accounts payable and accruals

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of convertible preferred stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

80

0

0

0

Accrued transaction costs on convertible senior notes

0

-

-

-

0

-

-

-

282

251

145

217

33

134

0

0

0

-

0

0

0

-

-

-

-

Cash paid for income taxes

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

299

393

488

583

676

780

886

895

802

775

786

920

1,182

0

0

0

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Conversion of Series E-1, E-2, E-3, E-4 and E-5 preferred stock into common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

123,982

0

0

0

Conversion of 2013 Notes into common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26,206

0

0

0

Issuance of common stock upon net exercise of common stock warrants in connection with IPO

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,490

0

0

0

Fair value in excess of debt host for derivative liabilities associated with convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,050

0

0

0

Deferred initial public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,028

0

0

0

Conversion of preferred stock warrants to common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,441

0

0

0

Termination of stock option repurchase right

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

58

0

0

0

Issuance of common stock warrants in connection with the 2013 Notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

981

0

0

0

Property and equipment purchases included in accounts payable and accruals

0

-

-

-

0

-

-

-

-

718

600

178

935

200

421

557

440

487

611

-116

-2,052

1,348

0

0

0

Accrued offering costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-